Abstract
ObjectiveThe aim of this study was to investigate the impact of pregabalin on pain, other symptoms, and patient-reported outcomes for patients with uncontrolled pain who have been referred to pain clinics.Patients and MethodsAdult patients with uncontrolled pain who had a score of ≥4 in the DN4 questionnaire were evaluated at baseline, month 3, and month 6. Evaluations included pain levels using a visual analog (VAS) scale as well as anxiety, depression, sleep, disability, and treatment satisfaction employing validated tools.ResultsOur sample comprised 413 patients who met the selection criteria, had not received pregabalin previously, and were prescribed pregabalin at the study initiation, mainly (97 %) as add-on therapy. Overall, patients had a statistically significant reduction in VAS pain score of 41 points (54 % reduction, p < 0.001), varying from 64 % reduction (oncological pain) to 31 % reduction (central neuropathic pain). Effect sizes for anxiety, depression, sleep, and treatment satisfaction improvement were moderate to large depending on the dimension and clinical entity.ConclusionOur results suggest that in patients with uncontrolled neuropathic pain of various origins who were treated at pain clinics, the addition of pregabalin to a wider pharmacological treatment regimen was associated with a clinically relevant improvement of pain and psychological well-being and a reduction in the impact of neuropathic pain on daily activities. Add-on treatment with pregabalin was well tolerated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.